Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:elexacaftor
gptkb:ivacaftor gptkb:tezacaftor |
| gptkbp:alternativeName |
gptkb:Trikafta
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_Kingdom gptkb:United_States |
| gptkbp:ATCCode |
gptkb:R07AX31
|
| gptkbp:form |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kaftrio
|
| gptkbp:indication |
cystic fibrosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
CFTR modulator
|
| gptkbp:pregnancyCategory |
not recommended unless clearly necessary
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
headache rash upper respiratory tract infection increased liver enzymes |
| gptkbp:usedFor |
patients with at least one F508del mutation in the CFTR gene
|
| gptkbp:bfsParent |
gptkb:elexacaftor
|
| gptkbp:bfsLayer |
7
|